Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy

Cancer

Volumn 116, Issue 12, 2010, Pages 2890-2901

  Yhim, Ho Young ^a   Han, Sae Won ^a   Oh, Do Youn ^a,b   Han, Wonshik ^a   Im, Seock Ah ^a,b   Kim, Tae You ^a,b   Kim, Young Tae ^a   Noh, Dong Young ^a   Chie, Eui Kyu ^a   Ha, Sung Whan ^a   Park, In Ae ^a   Bang, Yung Jue ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Breast cancer; Lung metastasis; Prognostic factors; Pulmonary metastasectomy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; METHOTREXATE; NAVELBINE; PLATINUM DERIVATIVE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE INTERVAL; FEMALE; HUMAN; LUNG METASTASIS; LUNG SURGERY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PNEUMONECTOMY; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 77954019311     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25054     Document Type: Article

References (28)

1. Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am. 2003;12:165-192, xi.
2. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25:4575-4580.
3. Hofmann HS, Neef H, Krohe K, Andreev P, Silber RE. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol. 2005;48:77-81, discussion 81-72.
4. Fourquier P, Regnard JF, Rea S, Levi JF, Levasseur P. Lung metastases of renal cell carcinoma: results of surgical resection. Eur J Cardiothorac Surg. 1997;11:17-21. (Pubitemid 27076108)
5. van Geel AN, Pastorino U, Jauch KW, et al. Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer. 1996;77:675-682. (Pubitemid 26055392)
6. Rehders A, Hosch SB, Scheunemann P, Stoecklein NH, Knoefel WT, Peiper M. Benefit of surgical treatment of lung metastasis in soft tissue sarcoma. Arch Surg. 2007;142:70-75, discussion 76. (Pubitemid 46106049)
7. Ollila DW. Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol. 2006;7:919-924. (Pubitemid 44615951)
8. Neuman HB, Patel A, Hanlon C, Wolchok JD, Houghton AN, Coit DG. Stage-IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol. 2007;14:2847-2853. (Pubitemid 47460630)
9. Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006;24:2743-2749. (Pubitemid 46630571)
10. Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol. 1983;23:175-180. (Pubitemid 13035296)
11. Diaz-Canton EA, Valero V, Rahman Z, et al. Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. The University of Texas M. D. Anderson Cancer Center experience and review of the literature. Ann Oncol. 1998;9:413-418.
12. Rahman ZU, Frye DK, Smith TL, et al. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer. 1999;85:104-111.
13. Chen F, Fujinaga T, Sato K, et al. Clinical features of surgical resection for pulmonary metastasis from breast cancer. Eur J Surg Oncol. 2009;35:393-397.
14. Friedel G, Pastorino U, Ginsberg RJ, et al. Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases. Eur J Cardiothorac Surg. 2002;22:335-344. (Pubitemid 36153060)
15. Lanza LA, Natarajan G, Roth JA, Putnam JB Jr. Long-term survival after resection of pulmonary metastases from carcinoma of the breast. Ann Thorac Surg. 1992;54:244-247, discussion 248.
16. Ludwig C, Stoelben E, Hasse J. Disease-free survival after resection of lung metastases in patients with breast cancer. Eur J Surg Oncol. 2003;29:532-535. (Pubitemid 37009971)
17. Yoshimoto M, Tada K, Nishimura S, et al. Favourable long-term results after surgical removal of lung metastases of breast cancer. Breast Cancer Res Treat. 2008;110:485-491. (Pubitemid 351962594)
18. Koodziejski L, Goralczyk J, Dyczek S, Duda K, Nabiaek T. The role of surgery in lung metastases. Eur J Surg Oncol. 1999;25:410-417.
19. Welter S, Jacobs J, Krbek T, Totsch M, Stamatis G. Pulmonary metastases of breast cancer. When is resection indicated? Eur J Cardiothorac Surg. 2008;34:1228-1234.
20. Rena O, Papalia E, Ruffini E, et al. The role of surgery in the management of solitary pulmonary nodule in breast cancer patients. Eur J Surg Oncol. 2007;33:546-550. (Pubitemid 46746529)
21. Anderson JR, Bernstein L, Pike MC. Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis. Biometrics. 1982;38:407-416. (Pubitemid 13274242)
22. Uhm JE, Park YH, Yi SY, et al. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer. 2009;124:1457-1462.
23. Rhee J, Han SW, Oh DY, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer. 2008;8:307.
24. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-10874. (Pubitemid 32878711)
25. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265-4274. (Pubitemid 46207001)
26. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792. (Pubitemid 32222155)
27. Borst P, Jonkers J, Rottenberg S. What makes tumors multidrug resistant? Cell Cycle. 2007;6:2782-2787.
28. Goldie JH, Coldman AJ. Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep. 1983;67:923-931.